341,444 Shares in Elanco Animal Health Incorporated $ELAN Purchased by OP Asset Management Ltd

OP Asset Management Ltd acquired a new stake in Elanco Animal Health Incorporated (NYSE:ELAN) in the first quarter, HoldingsChannel.com reports. The fund acquired 341,444 shares of the company’s stock, valued at approximately $8,171,000.

Other institutional investors also recently added to or reduced their stakes in the company. NewEdge Advisors LLC increased its position in Elanco Animal Health by 133.7% during the 4th quarter. NewEdge Advisors LLC now owns 1,096 shares of the company’s stock worth $25,000 after purchasing an additional 627 shares during the period. Huntington National Bank lifted its holdings in shares of Elanco Animal Health by 136.7% in the 3rd quarter. Huntington National Bank now owns 1,882 shares of the company’s stock valued at $38,000 after buying an additional 1,087 shares during the period. Root Financial Partners LLC boosted its stake in shares of Elanco Animal Health by 50.7% in the fourth quarter. Root Financial Partners LLC now owns 1,759 shares of the company’s stock valued at $40,000 after buying an additional 592 shares in the last quarter. Uniplan Investment Counsel Inc. purchased a new stake in shares of Elanco Animal Health in the fourth quarter valued at approximately $41,000. Finally, Torren Management LLC acquired a new position in Elanco Animal Health during the fourth quarter worth $46,000. Hedge funds and other institutional investors own 97.48% of the company’s stock.

Analyst Ratings Changes

ELAN has been the subject of several research analyst reports. UBS Group reiterated a “buy” rating on shares of Elanco Animal Health in a research report on Tuesday, March 10th. Wall Street Zen cut shares of Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a research note on Sunday, May 24th. Weiss Ratings downgraded shares of Elanco Animal Health from a “sell (d+)” rating to a “sell (d)” rating in a report on Monday, May 11th. JPMorgan Chase & Co. raised their price objective on shares of Elanco Animal Health from $28.00 to $30.00 and gave the company an “overweight” rating in a research note on Thursday, May 7th. Finally, TD Cowen boosted their price objective on shares of Elanco Animal Health from $31.00 to $32.00 and gave the stock a “buy” rating in a report on Thursday, June 18th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $28.55.

Elanco Animal Health Stock Up 1.7%

Elanco Animal Health stock opened at $24.36 on Friday. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.12 and a current ratio of 2.16. The firm has a market capitalization of $12.17 billion, a price-to-earnings ratio of -48.72, a price-to-earnings-growth ratio of 1.57 and a beta of 1.69. Elanco Animal Health Incorporated has a fifty-two week low of $13.39 and a fifty-two week high of $27.72. The stock’s fifty day moving average is $23.02 and its two-hundred day moving average is $23.55.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $0.40 earnings per share for the quarter, beating analysts’ consensus estimates of $0.34 by $0.06. The business had revenue of $1.37 billion during the quarter, compared to analysts’ expectations of $1.28 billion. Elanco Animal Health had a positive return on equity of 7.42% and a negative net margin of 4.95%.The business’s revenue for the quarter was up 14.9% on a year-over-year basis. During the same quarter last year, the business posted $0.37 earnings per share. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. Analysts predict that Elanco Animal Health Incorporated will post 1.11 EPS for the current fiscal year.

Insider Activity

In other Elanco Animal Health news, CEO Jeffrey N. Simmons purchased 4,971 shares of Elanco Animal Health stock in a transaction on Friday, May 15th. The shares were bought at an average price of $20.09 per share, with a total value of $99,867.39. Following the completion of the acquisition, the chief executive officer directly owned 171,971 shares of the company’s stock, valued at approximately $3,454,897.39. This trade represents a 2.98% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Rajeev A. Modi purchased 4,911 shares of the stock in a transaction dated Friday, May 15th. The stock was acquired at an average price of $20.35 per share, for a total transaction of $99,938.85. Following the completion of the transaction, the insider directly owned 160,812 shares of the company’s stock, valued at approximately $3,272,524.20. The trade was a 3.15% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Company insiders own 1.14% of the company’s stock.

Elanco Animal Health Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.